The present disclosure provides antibodies that bind to the prolactin receptor (PRLR) and methods of use thereof. In certain embodiments, the antibodies of the present disclosure bind to human PRLR with high affinity. In certain embodiments, the disclosure includes antibodies that bind to PRLR and block prolactin-mediated cell signaling. In other embodiments, the disclosure includes antibodies that bind to PRLR but do not block prolactin-mediated cell signaling. The antibodies of the present disclosure may be fully human antibodies. The disclosure includes anti-PRLR antibodies conjugated to cytotoxic agents, radionuclides, or other moieties that are detrimental to cell growth or proliferation. The antibodies of this disclosure are useful for the treatment of various cancers and other PRLR-related disorders. The present disclosure relates to an antibody drug conjugate comprising an antibody or antigen-binding fragment thereof that specifically binds to a class I cytokine receptor, wherein the antibody or antigen-binding fragment thereof is conjugated to a cytotoxic agent Also included are drug conjugates. [Selection figure] None
